Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Philip Morris International Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $284.5B | |
|---|---|---|
| Revenue (ttm) | 43.1B | |
| Net income (ttm) | 10.7B | |
| EPS (ttm) | $6.85 | |
| Shares out | 1.6B | |
| P/E (trailing) | 29.6x | |
| P/E (forward) | 20.4x | |
| Dividend | $6.40 (3.16%) | |
| Volume | 2,235,197 | |
| Beta | 0.36 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $31.41B | $31.76B | $35.17B | $37.88B | $40.65B | +6.7% |
| Gross profit | $21.38B | $20.36B | $22.28B | $24.55B | $27.28B | +6.3% |
| Operating income | $12.98B | $12.25B | $11.56B | $13.40B | $14.89B | +3.5% |
| Net income | $9.11B | $9.05B | $7.81B | $7.06B | $11.35B | +5.6% |
| EPS (diluted) | $5.83 | $5.81 | $5.02 | $4.52 | $7.26 | +5.6% |
| EBITDA | $2.93B | $13.48B | $13.37B | $15.75B | $17.46B | +56.3% |
| R&D | $617.0M | $642.0M | $709.0M | $759.0M | $756.0M | +5.2% |
| SG&A | $8.42B | $8.11B | $10.06B | $11.15B | $11.75B | +8.7% |
Recent company headlines from major financial publishers.
The base path requires FY2027 revenue and adjusted EPS near analyst forecasts as of 2026-09-09. Each annual update should test whether Europe revenue growth remains positive and reported profit keeps turning into operating cash. Europe stagnation or weaker cash generation would disconfirm the path.
The path gains support if FY2027 revenue and adjusted EPS exceed dated expectations while free cash flow remains strong. Positive Europe growth must also continue; Europe stagnation would disconfirm the path.
| Ke ↓ / g → | 2.6% | 3.1% | 3.6% | 4.1% | 4.6% |
|---|---|---|---|---|---|
| 5.6% | $285 | $324 | $392 | $559 | $587 |
| 6.4% | $244 | $265 | $296 | $346 | $447 |
| 7.1% | $217 | $230 | $249 | $273 | $311 |
| 7.8% | $199 | $207 | $219 | $233 | $254 |
| 8.5% | $185 | $191 | $199 | $208 | $221 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |